Botensilimab not checked

Agenus Inc. · AGEN1181 · Anti-CTLA-4

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
9 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.”In the company’s words, NCT05608044 on ClinicalTrials.gov
Tested for
Metastatic Colorectal Cancer, Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer and 1 more
Main trialPhase 2
“This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.”In the company’s words, NCT05608044 on ClinicalTrials.gov
Other names
AGEN1181 · Anti-CTLA-4

Other drugs for Metastatic Colorectal Cancer

All 393 drugs for Metastatic Colorectal Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Sep 2027 A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Phase 1Active, not recruiting 13 Jan 2025 Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Phase 2Completed 5 Jan 2026 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Phase 2Terminated 27 Apr 2026 A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Phase 1Completed 22 Feb 2024 Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Phase 1Completed 23 Dec 2024 Study of AGEN1571 in Participants With Advanced Solid Tumors
Phase 2Authorised not given WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY
Phase 2Authorised not given Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
Phase 3Authorised not given CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Botensilimab

Following is part of Solo: you see every change to Botensilimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in